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A B S T R A C T
Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch type (HCHWA-D) is an autosomal dominant hereditary disease caused by a point mutation in exon 17 of
the APP gene. We generated human induced pluripotent stem cells (hiPSCs) from a symptomatic HCHWA-D patient by using non-integrating Sendai virus (SeV). The
newly generated hiPSCs express all pluripotency markers, have a normal karyotype, carry the Dutch mutation, can diﬀerentiate in the three germ layers in vitro and
are SeV free.
Resource table
Unique stem cell lines i-
dentiﬁer
LUMCi005-A
LUMCi005-B
LUMCi005-C
Alternative names of ste-
m cell lines
LUMCi005-A: LUMC0074iHCHWAD01 and Lu074i#1
LUMCi005-B: LUMC0074iHCHWAD03 and Lu074i#3
LUMCi005-C: LUMC0074iHCHWAD07 and Lu074i#7
Institution Leiden University Medical Center (LUMC), Leiden, The
Netherlands
Contact information of
distributor
Dr. Willeke M.C van Roon-Mom, W.M.C.van_Roon@
lumc.nl
Type of cell lines hiPSCs
Origin Human
Cell Source Fibroblasts
Clonality Clonal
Method of reprogram-
ming
Non-integrating Sendai virus
Multiline rationale 3 clones of one disease cell line
Gene modiﬁcation Yes
Type of modiﬁcation Hereditary
Associated disease Hereditary Cerebral Hemorrhage with Amyloidosis-
Dutch type (HCHWA-D)
Gene/locus APP/21q21.3, Dutch mutation/ Chr21:25891856 G>C
Method of modiﬁcation N/A
Name of transgene or re-
sistance
N/A
Inducible/constitutive s-
ystem
N/A
Date archived/stock date 21/09/2015
Cell line repository/bank https://hpscreg.eu/cell-line/LUMCi005-A
https://hpscreg.eu/cell-line/LUMCi005-B
https://hpscreg.eu/cell-line/LUMCi005-C
Ethical approval NL45478.058.13/P13.080, Medical Ethical Committee
(MEC), Leiden University Medical Center (LUMC)
1. Resource utility
The generated hiPSCs are useful to study HCHWA-D disease me-
chanisms, as well as for drug discovery and disease modeling.
2. Resource details
Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch type
(HCHWA-D) is a hereditary autosomal dominant disease, clinically
characterized by recurrent intracerebral hemorrhage (ICH) and
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dementia with amyloid beta (Aβ) deposition in the cerebral leptome-
ningeal and cortical blood vessels. HCHWA-D mutation carriers usually
get their ﬁrst ICH at the age of 50 with multiple recurrences in the years
thereafter. Because of the similarities in Aβ composition and clinical
symptoms HCHWA-D is considered to be a model for sporadic cerebral
amyloid angiopathy. HCHWA-D is caused by a G to C transversion in
codon 693 of the APP gene that results in a Gln-to-Glu (NP_000475.1:p.
Glu693Gln) amino acid substitution, that is located within the Aβ se-
quence of APP (E22Q) (Bornebroek et al., 1996; Kamp et al., 2014).
Fibroblasts, derived from a patient skin biopsy were successfully re-
programmed into hiPSCs using a replication defective and persistent
Sendai virus (SeV) vector installed with OCT4, SOX2, KLF4 and c-Myc
(Nishimura et al., 2011). The three hiPSC clones that were derived from
patient HCHWA-D ﬁbroblasts were named LUMCi005-A, LUMCi005-B
and LUMCi005-C (Table 1). All hiPSC clones showed typical hiPSC-like
morphology with small and tightly packed cells, a high nucleus to cy-
toplasm ratio, and well deﬁned nucleoli (Fig. 1A). Moreover, all clones
were SeV negative at passage 5 as conﬁrmed by Q-RT-PCR (Supple-
mentary Fig. S1) and express the pluripotency markers OCT3/4,
NANOG and SSEA-4 (Fig. 1B). In accordance with the immuno-
ﬂuorescence results, the generated hiPSCs showed upregulated ex-
pression of the pluripotency genes OCT4, NANOG and SOX2 compared
to ﬁbroblasts (Fig. 1C). A routine Global Screening Array (GSA) was
performed to check for copy number variants (CNV) or allelic changes
and to compare the identities of the ﬁbroblasts and derived hiPSCs.
Although the resolution of the GSA array is higher compared to con-
ventional karyotyping, the GSA assay, however, cannot detect balanced
translocations. Using a report resolution of ~50 kb, no chromosomal
abnormalities were observed (Fig. 1D). Furthermore, the newly derived
hiPSCs were identical to the patient-derived ﬁbroblasts (Supplementary
Fig. S1). The Dutch mutation was conﬁrmed in all three clones by
Sanger sequencing (Fig. 1E). In addition, all clones showed spontaneous
diﬀerentiation in vitro into the three germ layers, as conﬁrmed by im-
munoﬂuorescent stainings for the endodermal marker α-fetoprotein
(AFP), the mesodermal marker PECAM-1 (CD31), and the ectodermal
marker β3-tubulin (TUBB3) (Fig. 1F). All hiPSCs were tested for the
Apolipoprotein E (ApoE) genotype using the melting curve assay.
Apolipoprotein E is a protein with multiple roles in lipid metabolism,
neurobiology and neurodegenerative diseases that have been im-
plicated with amyloidopathies. The ApoE2 genotype was shown to be
protective, ApoE3 to be neutral and the ApoE4 genotype to be detri-
mental (Huang et al., 2014). All lines contained an ApoE3/4 genotype.
Finally all cell lines were negative in regular tests for mycoplasma
(Supplementary Fig. S1). All data mentioned are presented in Table 2.
3. Materials and methods
3.1. Ethical statement
This study was approved by the LUMC Medical Ethical Committee
(MEC) and informed consent was obtained from the HCHWA-D patient
(NL45478.058.13/P13.080).
3.2. Generation of hiPSCs
A skin biopsy was obtained from 56-year old symptomatic HCHWA-
D patient. Following dissection, ﬁbroblasts were cultured in minimum
essential medium supplemented with 15% FBS, 2mM GlutaMAX and
1% penicillin-streptomycin (all ThermoFisher) at 37 °C and 5% CO2.
Fibroblasts were expanded up to passage three and then frozen in liquid
nitrogen for future use. For reprogramming 1×105 ﬁbroblasts were
transduced with 7.5 MOI SeVdp (KOSM) 302 L and seeded on irradiated
mouse embryonic ﬁbroblasts (MEFs) in ﬁbroblast media 24 h later. The
following day, cells were cultured in DMEM/F12 Glutamax medium
supplemented with 20% KnockOut Serum Replacement (KOSR), Non-
Essential Amino Acids (NEAA), 2-mercaptoethanol, penicillin-strepto-
mycin (all Gibco) and 10 ng/ml bFGF (Peprotech) until the formation of
hiPSC colonies, around 3weeks later. hiPSC colonies were picked
manually and expanded on Vitronectin XF coated plates in TESR-E8
media according to manufacturer's instructions (STEMCELL
Technologies). hiPSCs were passaged once per week and within the ﬁrst
ﬁve passages the splitting ratio went from 1:2 to 1:10. The cells were
dissociated using the gentle cell dissociation reagent (GCDR) (STEMC-
ELL Technologies).
Table 1
Summary of lines.
hiPSC line names Abbreviation in ﬁgures Gender Age Ethnicity Genotype of locus Disease
LUMCi005-A Lu074i#1 Female 56 Caucasian Chr21:25891856 G>C HCHWA-D
LUMCi005-B Lu074i#3 Female 56 Caucasian Chr21:25891856 G>C HCHWA-D
LUMCi005-C Lu074i#7 Female 56 Caucasian Chr21:25891856 G>C HCHWA-D
Table 2
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Brightﬁeld microscopy Normal morphology Fig. 1 panel A
Phenotype Qualitative analysis of
immunoﬂuorescent staining
Positive immunostaining of the pluripotency markers OCT4,
NANOG and SSEA-4
Fig. 1 panel B
Quantitative analysis by RT-qPCR Expression of the pluripotency markers OCT4, NANOG and SOX2 Fig. 1 panel C
Genotype GSAMD24 v1 Illumina Inﬁnium SNP
array 700 k
CNV report resolution ~50 kb: No major copy number variations
or allelic changes for Lu074i#1, Lu074i#3 and Lu074i#7
Fig. 1 panel D
Identity GSAMD24 v1 Illumina Inﬁnium SNP
array 700 k
Fibroblasts and hiPSCs have > 99,99% identical SNPs Summarized data in Fig. S1. Raw data
available with the authors.
Mutation analysis Sanger Sequencing All hiPSC clones have the heterozygous Chr21:25891856 G>C
mutation
Fig. 1 panel E
Southern Blot OR WGS N/A
Microbiology and
virology
Mycoplasma Mycoplasma testing by luminescence: Negative Fig. S1
Diﬀerentiation potential Qualitative analysis of
immunoﬂuorescent staining
Positive immunostaining of the three germ layers markers AFP
(endoderm), CD31 (mesoderm) and TUBB3 (ectoderm)
Fig. 1 panel F
Donor screening N/A
Genotype additional info ApoE genotyping by melting curve
analysis
All clones have ApoE genotype ApoE3/4 Data available with the authors
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3.3. Spontaneous in vitro diﬀerentiation of hiPSCs
Undiﬀerentiated hiPSC colonies were scraped after incubation with
Gentle Cell Dissociation Reagent (STEMCELL Technologies) and large
pieces were plated on Vitronectin XF coated glass coverslips in TESR-E8
media consistent with manufacturer's protocol (STEMCELL
Technologies). After 1 day cells were cultured in DMEM/F12 with 20%
FBS for three weeks with media changes every other day.
3.4. Immunoﬂuorescent staining
For immunoﬂuorescent staining hiPSCs were ﬁrst ﬁxed in 2% par-
aformaldehyde for 30min at RT, permeabilized with 0.1% Triton X-100
and blocked with 4% normal swine serum (NSS, DAKO) for 1 h at RT.
Then cells were incubated with primary antibodies in 4% NSS, O/N at
4 °C followed by probing with secondary ﬂuorescent dye labelled an-
tibodies for 1 h at RT. DAPI was used as nuclear counter staining.
Antibodies are listed in Table 3. Images were generated using a Leica
TCS SP8.
3.5. RNA isolation and RT-qPCR
The ReliaPrep™ Miniprep System (Promega) was used for RNA
isolation according to manufacturer's instructions. 500 ng of RNA per
reaction were used for cDNA synthesis using the transcriptor ﬁrst strand
cDNA synthesis kit (Roche). Cycling parameters of the qPCR included
an initial denaturation at 95 °C for 10 s, annealing at 60 °C for 30 s and
extension at 72 °C for 20 s. The RT-qPCR reaction was run on a
LightCycler 480 Real-Time PCR System (Roche) with SensiMix SYBR
Hi-ROX Kit (Bioline). CT-values were normalized to GAPDH using the
ΔΔCT-method. Primer sequences are listed in Table 3.
3.6. Genomic DNA isolation
The Wizard Genomic DNA puriﬁcation Kit (Promega) was used for
genomic DNA isolation according to the manufacturer's instructions.
3.7. Sanger sequencing
To conﬁrm the presence of the Dutch mutation in the APP gene,
100 ng of gDNA from all 3 clones was used for PCR (T100 Thermal
Cycler, Bio-Rad). Cycle parameters were an initial denaturation at
95 °C, followed by 39 cycles of denaturation at 95 °C for 15 s, annealing
at 60 °C for 15 s and elongation at 72 °C for 30 s. Final elongation step at
72 °C for 7min. Primer sequences are listed in Table 3. PCR samples
were submitted for Sanger sequencing and sequences were checked
with the SnapGene software.
3.8. ApoE genotyping
To check the ApoE variant that is present in the hiPSC lines, 100 ng
of gDNA from all 3 clones was used for RT-PCR (DNA engine, Bio-Rad).
Cycle parameters were initial denaturation at 95 °C for 10min, followed
by 40 cycles of denaturation at 95 °C for 15 s, annealing at 64 °C for 30 s
and extension at 72 °C for 30 s. Final elongation step at 72 °C for 5min.
Then PCR samples were inserted in the Lightscanner 96 Hi-res Melting
System (Idaho Technologies) for the melting curve assay, with starting
temperature at 75 °C and ending temperature at 98 °C. Results were
analyzed with the Lightscanner software.
3.9. Mycoplasma detection
The MycoAlert™ Mycoplasma Detection Kit (Lonza) Tests were used
for testing mycoplasma presence in the cell cultures according to the
manufacturer's instructions.
3.10. Global screening array
The Global Screening Array (GSA) (Illumina) was used according to
standard procedures, followed by an analysis in GenomeStudio software
(Illumina) using the GSA manifest ﬁles. GenomeStudio ﬁnal reports
were used to analyze and visualize in Nexus Discovery (BioDiscovery El
Segundo). A report resolution of ~50 kb was used to analyze the data
for chromosomal aberrations. To compare the patient ﬁbroblasts with
the generated hiPSCs the array ﬁnal reports were selected as input for
an R script. The ﬁles were transformed into smaller tables based on
their SNP ID. Using statistics we determined whether the allelic calls
matched, mismatched or failed.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2018.101359.
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